[go: up one dir, main page]

MX2018010247A - Nuevos conjugados de amanitina. - Google Patents

Nuevos conjugados de amanitina.

Info

Publication number
MX2018010247A
MX2018010247A MX2018010247A MX2018010247A MX2018010247A MX 2018010247 A MX2018010247 A MX 2018010247A MX 2018010247 A MX2018010247 A MX 2018010247A MX 2018010247 A MX2018010247 A MX 2018010247A MX 2018010247 A MX2018010247 A MX 2018010247A
Authority
MX
Mexico
Prior art keywords
amatoxin
conjugate
target
amino acid
binding moiety
Prior art date
Application number
MX2018010247A
Other languages
English (en)
Inventor
Anderl Jan
Simon Werner
Müller Christoph
Lutz Christian
Hechler Torsten
Werner-Simon Susanne
Kulke Michael
Original Assignee
Heidelberg Pharma Res Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Res Gmbh filed Critical Heidelberg Pharma Res Gmbh
Publication of MX2018010247A publication Critical patent/MX2018010247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a un conjugado que comprende (a) una amatoxina que comprende (i) un aminoácido 4 con una posición 6'-desoxi; y (ii) un aminoácido 8 con una posición S-desoxi; (b) un resto de unión a diana; y (c) opcionalmente un engarce que une dicha amatoxina y dicho resto de unión a diana. La invención se refiere además a una composición farmacéutica que comprende dicho conjugado.
MX2018010247A 2016-03-03 2017-03-02 Nuevos conjugados de amanitina. MX2018010247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16000511.2A EP3222292A1 (en) 2016-03-03 2016-03-03 Amanitin conjugates
PCT/EP2017/054911 WO2017149077A1 (en) 2016-03-03 2017-03-02 Amanitin conjugates

Publications (1)

Publication Number Publication Date
MX2018010247A true MX2018010247A (es) 2018-12-19

Family

ID=55456549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010247A MX2018010247A (es) 2016-03-03 2017-03-02 Nuevos conjugados de amanitina.

Country Status (25)

Country Link
US (2) US11590238B2 (es)
EP (2) EP3222292A1 (es)
JP (2) JP7084313B2 (es)
KR (1) KR102466933B1 (es)
CN (1) CN108778341B (es)
AU (1) AU2017228020B2 (es)
BR (1) BR112018067615A2 (es)
CL (1) CL2018002502A1 (es)
CO (1) CO2018009533A2 (es)
CY (1) CY1125428T1 (es)
DK (1) DK3423104T5 (es)
ES (1) ES2925006T3 (es)
HR (1) HRP20220948T1 (es)
HU (1) HUE059360T2 (es)
LT (1) LT3423104T (es)
MX (1) MX2018010247A (es)
NZ (1) NZ745508A (es)
PL (1) PL3423104T3 (es)
PT (1) PT3423104T (es)
RS (1) RS63451B1 (es)
RU (1) RU2753416C2 (es)
SG (2) SG11201807472TA (es)
SI (1) SI3423104T1 (es)
WO (1) WO2017149077A1 (es)
ZA (1) ZA201805336B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471772A4 (en) 2016-06-17 2020-03-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
WO2018115466A1 (en) 2016-12-23 2018-06-28 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
EP3738608A4 (en) * 2017-08-18 2021-12-08 Sichuan Baili Pharm Co. Ltd NON-NATURAL AMATOXIN TYPE ANTIBODY CONJUGATE
KR20190043031A (ko) * 2017-10-17 2019-04-25 한국화학연구원 아마톡신 유도체 및 이의 제조방법
US11400165B2 (en) * 2017-11-04 2022-08-02 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
IL316155A (en) 2017-11-29 2024-12-01 Heidelberg Pharma Res Compositions and Methods for the Depletion of CD5(PLUS) CELLS
CN111867621A (zh) * 2018-01-18 2020-10-30 美真达治疗公司 用于耗尽cd134+细胞的组合物和方法
US20210077571A1 (en) * 2018-04-13 2021-03-18 Heidelberg Pharma Research Gmbh Targeted amatoxin conjugate for the treatment of solid tumors
CN112566671A (zh) * 2018-06-07 2021-03-26 美真达治疗公司 使用抗体药物缀合物(adc)的治疗方法
CN112739339B (zh) 2018-07-23 2024-12-27 海德堡医药研究有限责任公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
AU2019311077B2 (en) 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
WO2020127968A1 (en) 2018-12-20 2020-06-25 Marino Stephen F Protein-drug conjugate comprising a monomeric form of proteinase 3
WO2020146432A1 (en) * 2019-01-07 2020-07-16 Magenta Therapeutics, Inc. Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy
AU2020263959A1 (en) 2019-04-24 2021-11-25 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
CN114144201B (zh) 2019-05-23 2024-10-01 海德堡医药研究有限责任公司 含可裂解连接基的抗体药物缀合物
SG11202113331QA (en) * 2019-06-04 2021-12-30 Magenta Therapeutics Inc Methods and compositions for treating autoimmune diseases
CN114080395A (zh) * 2019-07-05 2022-02-22 纯生物有机有限公司 α-鹅膏蕈碱及其衍生物的合成方法
EP3792250A1 (en) * 2019-09-13 2021-03-17 Pure Bioorganics SIA Synthesis of alpha-amanitin and its derivatives
AR120218A1 (es) * 2019-10-15 2022-02-02 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo específico de linfocitos b
WO2021250059A1 (en) * 2020-06-09 2021-12-16 Heidelberg Pharma Research Gmbh Method for synthesis of thioether-containing peptides
MX2023005192A (es) 2020-11-04 2023-05-15 Heidelberg Pharma Res Gmbh Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.
KR20230124953A (ko) * 2020-12-22 2023-08-28 추가이 세이야쿠 가부시키가이샤 혼합 용매에 의한 동결 건조 공정을 포함하는 의약품의제조 방법
AU2022236461A1 (en) 2021-03-19 2023-10-05 Heidelberg Pharma Research Gmbh B-lymphocyte specific amatoxin antibody conjugates
AU2023374571A1 (en) 2022-11-01 2025-04-03 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
ATE521366T1 (de) 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
CL2009000505A1 (es) 2008-03-05 2010-01-15 Biocryst Pharm Inc Compuestos derivados de triciclos nitrogenados, inhibodores de polimerasas de adn y arn virales; composicion farmaceutica que los comprende; y uso en el tratamiento de infecciones virales y cancer.
CA2756246A1 (en) 2009-04-08 2010-10-14 Heinz Faulstich Amatoxin-armed target-binding moieties for the treatment of cancer
US9233173B2 (en) 2009-04-08 2016-01-12 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
JP5954789B2 (ja) 2009-08-10 2016-07-20 ユーシーエル ビジネス パブリック リミテッド カンパニー 機能的分子の可逆的共有結合
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
EP2436398B1 (en) * 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkers
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
WO2013184514A1 (en) 2012-06-04 2013-12-12 Irm Llc Site-specific labeling methods and molecules produced thereby
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
PL2895513T3 (pl) * 2012-09-12 2018-11-30 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
CN105377304B (zh) * 2014-03-10 2018-05-15 海德堡医药有限责任公司 鹅膏毒肽衍生物
EP4115910A1 (en) * 2015-03-09 2023-01-11 Heidelberg Pharma Research GmbH Amatoxin-antibody conjugates
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition

Also Published As

Publication number Publication date
US12201693B2 (en) 2025-01-21
RU2018131636A3 (es) 2020-04-08
EP3423104B1 (en) 2022-05-18
JP7362714B2 (ja) 2023-10-17
RU2018131636A (ru) 2020-04-03
CN108778341A (zh) 2018-11-09
ZA201805336B (en) 2023-09-27
SG10201913942SA (en) 2020-03-30
BR112018067615A2 (en) 2018-12-26
LT3423104T (lt) 2022-08-10
RU2753416C2 (ru) 2021-08-16
US11590238B2 (en) 2023-02-28
HRP20220948T1 (hr) 2022-10-28
KR20180114191A (ko) 2018-10-17
JP7084313B2 (ja) 2022-06-14
PL3423104T3 (pl) 2022-09-19
SI3423104T1 (sl) 2022-09-30
PT3423104T (pt) 2022-08-22
JP2022028756A (ja) 2022-02-16
KR102466933B1 (ko) 2022-11-11
CY1125428T1 (el) 2025-05-09
WO2017149077A1 (en) 2017-09-08
AU2017228020A1 (en) 2018-09-06
DK3423104T5 (da) 2022-09-05
ES2925006T3 (es) 2022-10-13
CA3015138A1 (en) 2017-09-08
NZ745508A (en) 2023-05-26
RS63451B1 (sr) 2022-08-31
CO2018009533A2 (es) 2018-09-20
US20210138081A1 (en) 2021-05-13
EP3423104A1 (en) 2019-01-09
CN108778341B (zh) 2022-11-01
SG11201807472TA (en) 2018-09-27
DK3423104T3 (da) 2022-08-29
AU2017228020B2 (en) 2024-05-16
EP3222292A1 (en) 2017-09-27
CL2018002502A1 (es) 2019-02-22
HUE059360T2 (hu) 2022-11-28
JP2019511484A (ja) 2019-04-25
US20230233703A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
ZA201805336B (en) Amanitin conjugates
ZA201903667B (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
ZA202001747B (en) Psma-targeting amanitin conjugates
ZA201903062B (en) Amanitin antibody conjugates
WO2017031034A3 (en) Covalent linkers in antibody-drug conjugates and methods of making and using the same
MX2024002632A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
MX2017013154A (es) Conjugados anticuerpo-farmaco de sitio especifico.
MY206244A (en) Anti-muc1 antibody-drug conjugate
ZA201706745B (en) Site-specific antibody-drug conjugates
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
MX2019006983A (es) Conjugados de anticuerpo-farmaco de multiples farmacos.
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MX2020001212A (es) Conjugados anticuerpo-farmaco a base de antraciclina que tienen alta tolerabilidad in vivo.
WO2015151081A3 (en) Bridge linkers for conjugation of cell-binding molecules
WO2015151080A3 (en) Specific conjugation of cell-binding molecules
MX2015005124A (es) Conjugados de farmaco-proteina.
WO2017089890A8 (en) Conjugates comprising self-immolative groups and methods related thereto
WO2016147031A3 (en) Novel hydrophilic linkers and ligand-drug conjugates thereof
MX2017008215A (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
MX2017005199A (es) Conjugados y reactivos de conjugacion.
MX2017013171A (es) Conjugados anticuerpo-farmaco de sitio especifico.
MX2020012698A (es) Vectores mejorados de polietilenimina polietilenglicol.
MX2020001472A (es) Nuevo metodo para sintetizar amanitinas.
IL272931A (en) Peptide conjugates, conjugation process and their uses
ZA202101990B (en) Sulfomaleimide-based linkers and corresponding conjugates